News
NNVC
--
0.00%
--
FUBO, RKT, TRXC and SOS among midday movers
Gainers: Cohen & Company Inc. (COHN) +109%.Veritiv Corporation (VRTV) +62%.KemPharm, Inc. (KMPH) +36%.Ovid Therapeutics Inc. (OVID) +36%.Super League Gaming, Inc. (SLGG) +35%.MingZhu Logistics Holdings Limited (YGMZ) +32%.Asensus Surgical, Inc. (TRXC)
Seekingalpha · 4h ago
Ovid Therapeutics, KemPharm leads healthcare gainers; Vir Biotechnology, NanoViricides among major losers
Gainers: Ovid Therapeutics (OVID) +48%, KemPharm (KMPH) +46%, Ocugen (OCGN) +34%, Asensus Surgical (TRXC) +32%, Heat Biologics (HTBX) +16%.Losers: Vir Biotechnology (VIR) -29%, NanoViricides (NNVC) -16%, ASLAN Pharmaceuticals (ASLN) -11%, PLx Pharma (PLXP)...
Seekingalpha · 5h ago
DJ NanoViricides Shares Drop 12% After Big Jump Tuesday
Dow Jones · 7h ago
Rocket Companies, Magnolia Oil & Gas leads the premarket losers' pack
Luokung Technology (LKCO) -11%.Magnolia Oil & Gas (MGY) -11% on pricing 17M shares in secondary offering.Stratasys (SSYS) -10% on pricing ~7M stock offering.PLx Pharma (PLXP) -9% after proposed capital raise.STRATA Skin Sciences (SSKN) -8%.NanoViricides (N...
Seekingalpha · 8h ago
Mid-Afternoon Market Update: Crude Oil Down 1.5%; Communication Systems Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 0.08% to 31,562.10 while the NASDAQ fell 0.87% to 13,470.33. The S&P also fell, dropping 0.14% to 3,896.45.
Benzinga · 1d ago
DDD, NVAX, LMND and RKT among midday movers
Gainers: NanoViricides, Inc. (NNVC) +89%.Communications Systems, Inc. (JCS) +74%.Amyris, Inc. (AMRS) +41%.Hovnanian Enterprises, Inc. (HOV) +37%.Rocket Companies, Inc. (RKT) +36%.Perion Network Ltd. (PERI) +27%.The OLB Group, Inc. (OLB) +25%.Novan, Inc.
Seekingalpha · 1d ago
Mid-Day Market Update: Nasdaq Down 100 Points; NanoViricides Shares Spike Higher
Midway through trading Tuesday, the Dow traded down 0.18% to 31,478.24 while the NASDAQ fell 0.77% to 13,483.57. The S&P also fell, dropping 0.40% to 3,886.37.
Benzinga · 1d ago
NanoViricides, CHF Solutions leads healthcare gainers; FibroGen, Neuronetics among major losers
Gainers: NanoViricides NNVC +63%, CHF Solutions CHFS +25%, Avenue Therapeutics (ATXI) +19%, Fortress Biotech FBIO +17%, STRATA Skin Sciences (SSKN) +15%.Losers: FibroGen FGEN -30%, Neuronetics STIM -14%, RedHill Biopharma RDHL -13%, Morphic Holding (MORF) ...
Seekingalpha · 1d ago
DJ NanoViricides Shares Jump 68% on Effectiveness of Covid-19 Drug Candidates
Dow Jones · 1d ago
Mid-Morning Market Update: Markets Mostly Lower; Target Profit Tops Views
Following the market opening Tuesday, the Dow traded up 0.04% to 31,549.29 while the NASDAQ fell 0.52% to 13,518.42. The S&P also fell, dropping 0.20% to 3,894.08.
Benzinga · 1d ago
RKT, SOS, KOPN and PERI among premarket gainers
NanoViricides (NNVC) +112% on effectiveness of COVID-19 drug candidates in cell culture studies.Communications Systems (JCS) +38% after entering merger agreement with Pineapple Energy.STRATA Skin Sciences (SSKN) +30% on announcing CEO Transition.CHF Soluti...
Seekingalpha · 1d ago
The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 1)
Benzinga · 1d ago
DJ NanoViricides Reports Positive Results for Covid-19 Drug Candidates
Dow Jones · 1d ago
NanoViricides shares rally 29% on effectiveness of COVID-19 drug candidates in cell culture studies
NanoViricides (NNVC) soars 29% premarket following a report on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates.The Company studied the effectiveness of NV-CoV-2, NV-CoV-2-R and remdesivir against two unrelated
Seekingalpha · 1d ago
NanoViricides Press Release Highlights 'strong pan-coronavirus effectiveness' Of Its NV-CoV-2 And NV-CoV-2-R Candidates; Says Both Candidates Were 'found to be highly effective in comparison to remdesivir against two distinctly different coronaviruses'
SHELTON, CT / ACCESSWIRE / March 2, 2021 / NanoViricides, Inc. (NYSE:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicine technology
Benzinga · 1d ago
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application
March 02, 2021 (ACCESSWIRE via COMTEX) -- SHELTON, CT / ACCESSWIRE / March 2, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the...
ACCESSWIRE · 1d ago
NanoViricides Reports 'Strong Effectiveness' for COVID Drugs
NanoViricides shares are higher. One of its treatments combines Gilead's remdesivir with NanoViricides' offering.
TheStreet.com · 1d ago
Influenza A Virus, H3N2 Subtype Infections Drug Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast 2020 to 2027 By Ameco Research
Comserve · 02/22 11:15
H3N2 Infection Treatment Market Global Industry Insights, Trends, Size, Share, Outlook, And Opportunity Analysis, 2018-2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 05:51:29 / Comserve Inc. / -- H3N2 Infection Treatment market is segmented by Type, and by Application. Players, stakeholders,...
Comserve · 02/22 10:53
Corona Virus Treatment Market Share, Size, Growth, 2021 Industry Trends, Global Covid-19 Impact on Demand, Emerging Technologies, Sales Revenue, Key Players Analysis, Development Status, Opportunity Assessment and Industry Expansion Strategies 2025
Feb 22, 2021 (The Expresswire) -- Global "Corona Virus Treatment Market" report 2021 presents a point by point analysis of the key trends, opportunities,...
The Express Wire · 02/22 07:35
Webull provides a variety of real-time NNVC stock news. You can receive the latest news about NANOVIRICIDES through multiple platforms. This information may help you make smarter investment decisions.
About NNVC
NanoViricides, Inc. is a nano-biopharmaceutical research and development company. The Company is engaged the discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company provides nanoviricide technology, which enables direct attacks at multiple points on a virus particle. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection. The nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company’s lead product candidate is NV-HHV-101 in the HerpeCide program, as a skin cream for the treatment of shingles rash.